SecBot SecBot
6-K ·Filed Mar 26, 2026

BWAY

Brainsway Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001171843-26-001925
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor Neurolief's revenue trajectory for potential $5 million equity tranche trigger and assess likelihood of BrainsWay exercising its acquisition option. The FDA approval and VA access create near-term commercial upside for Neurolief, which could significantly enhance BrainsWay's long-term value if it exercises its call option.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.49
T+0 close · Mar 26, 2026 · via day close
Latest settled
+3.04%
T+60 · $13.90
Vs SPY
−10.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $13.49entry
  2. T+1 · 8mo ago −4.60%α −2.92% · $12.87
  3. T+5 · 8mo ago +0.59%α −1.04% · $13.57
  4. T+20 · 7mo ago +21.35%α +10.68% · $16.37
  5. T+60 · 5mo ago +3.04%α −10.91% · $13.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approval of Neurolief's ProlivRx system for treatment-resistant major depressive disorder. This brings BrainsWay's total investment in Neurolief to $11 million, with potential for an additional $5 million equity investment and a call option to acquire Neurolief outright.

Key Facts

  • BrainsWay invested an additional $6 million in Neurolief via a convertible loan, triggered by FDA PMA approval of ProlivRx for MDD.
  • Total investment by BrainsWay in Neurolief now stands at $11 million.
  • Potential for an additional $5 million equity investment if Neurolief hits a revenue-based target.
  • BrainsWay holds a call option to acquire all of Neurolief at a price based on enterprise value or revenue multiple.
  • ProlivRx is the first FDA-approved at-home neurostimulation device for treatment-resistant MDD.
  • Neurolief has secured placement on the VA Federal Supply Schedule, enabling access to the U.S. veterans healthcare system.

Financial Impact

$6 million in new capital deployed; total exposure now $11 million with potential for $5 million more; possible future acquisition of Neurolief.

cashdebtstrategic investment valuefuture acquisition cost

Risk Factors

  • Execution risk in Neurolief's commercialization of ProlivRx despite FDA approval.
  • Potential dilution or balance sheet impact if BrainsWay exercises future investment tranches or acquisition option.
  • Regulatory or reimbursement challenges for at-home neurostimulation adoption.

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-001925
Document: f6k_032526.htm0001171843-26-001925
Document: 0001171843-26-001925-index-headers.html0001171843-26-001925
Document: 0001171843-26-001925-index.html0001171843-26-001925
Document: 0001171843-26-001925.txt0001171843-26-001925

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026